XML 37 R14.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Cephalon and Teva Agreement | 6 Months Ended
--- | ---
Oct. 31, 2013
Cephalon and Teva Agreement [Abstract] |
Cephalon and Teva Agreement [Text Block] | Note 8. Cephalon and Teva Agreement On March 16, 2011, the Company entered into an agreement with Cephalon, Inc., or Cephalon,, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., or Teva, pursuant to which the Company agreed to conduct TumorGraft studies on two proprietary chemical compounds provided by Cephalon to determine the activity or response of these compounds in potential clinical indications. Under certain conditions, Cephalon reserved the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments, which are $460,000 for one compound and $880,000 for the other compound. On November 30, 2012, Cephalon exercised the option to pay this one-time fee of $880,000 to the Company, in lieu of any future milestone or royalty payments, for one compound tested under the agreement described above. Written notice was provided to the Company on December 3, 2012 and payment was received on December 19, 2012. This fee has been recognized as revenue during the third quarter of fiscal 2013. During fiscal 2013, the agreement with Cephalon was amended to perform additional services for an increased fee of $277,000. As models, along with required reports, are delivered, revenue is recognized on a performance basis in accordance with the Company’s revenue recognition policies. Revenues of $133,000 and $237,000 were recognized during the six months ended October 31, 2013 and 2012, respectively, which are independent of the $880,000 noted above. On July 30, 2013, the Company entered into an agreement with Teva pursuant to which the Company agreed to conduct TumorGraft studies on multiple proprietary chemical compounds provided by Teva to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Teva agreed to, pay an upfront payment and, under certain conditions, pay the Company various amounts upon achieving certain milestones, based on the performance of the compounds in preclinical testing and dependent upon testing the compound in clinical settings and obtaining FDA approval. In addition, Teva agrees to pay the Company royalties on any commercialized products developed under the agreement. This agreement terminates the collaborative agreement noted above between Cephalon and the Company.

X
- Details
Name: | csbr_CephalonAndTevaAgreementAbstract
Namespace Prefix: | csbr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure relating to Cephalon and Teva Agreement. + References No definition available. + Details
Name: | csbr_CephalonAndTevaAgreementTextBlock
Namespace Prefix: | csbr_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration